Status:
COMPLETED
Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Migraine
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to investigate the efficacy and safety of telcagepant (MK-0974) compared to an approved medication for acute migraine. This study was conducted as a "triple-dummy" design;...
Eligibility Criteria
Inclusion
- Has at least 1 year history of migraine (with or without aura)
- Females of child bearing potential must use acceptable contraception throughout trial.
Exclusion
- Is pregnant/breast-feeding (or is a female expecting to conceive during study period)
- Has history or evidence of stroke/transient ischemic attacks, heart disease, coronary artery vasospasm, other significant underlying cardiovascular diseases, uncontrolled hypertension (high blood pressure), uncontrolled diabetes, or human immunodeficiency virus (HIV) disease
- Has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other than migraine)
- Has a history of gastric, or small intestinal surgery, or has a disease that causes malabsorption
- Has a history of cancer within the last 5 years.
Key Trial Info
Start Date :
February 15 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 2 2007
Estimated Enrollment :
1380 Patients enrolled
Trial Details
Trial ID
NCT00442936
Start Date
February 15 2007
End Date
October 2 2007
Last Update
October 17 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.